Applied DNA Q2 revenue down 79% to $930k; operating loss widens to $3.6M

BNB PLUS CORP.

2024-Q2 EPS reported -$7.47 revenue$1,820,795

Total revenue $930k vs $4.4M YoY; COVID testing contract with CUNY ended June 2023.
Gross profit declined to $296k (32% margin) from $1.8M (41%) YoY.
Operating loss $3.6M vs $2.7M YoY; adjusted EBITDA -$3.3M.
Cash $3.1M as of March 31, 2024, down from $7.2M at Sept 30, 2023.
Effected 1-for-20 reverse stock split on April 25, 2024; regained Nasdaq bid price compliance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

BNB PLUS CORP. reported second fiscal quarter ended March 31, 2024 results: revenue approximately $930 thousand.

Period: second fiscal quarter ended March 31, 2024
Revenue: approximately $930 thousand
Result: reported results

Exact text from the filing

reporting period. The Company will host an investor update call on June 12, 2024. Summary Second Quarter Fiscal 2024 Financial Results: ● Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter of fiscal 2023. The decrease in revenue of approximately $3.5 million was due to an

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-24-059893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.